Turkish Researchers Revise Efficacy Rate for Sinovac’s COVID-19 Vaccine

More than two months after Turkey granted emergency approval for the COVID-19 vaccine made by China’s Sinovac Biotech, Turkish researchers have revised the efficacy rate of the shot in preventing COVID-19 to 83.5 percent from 91.25 percent based on finalized phase 3 data.

The vaccine, known as CoronaVac, did stay at 100 percent efficiency in preventing hospitalization and severe illness, however. No deaths were seen in the Turkish trials, which enrolled a total of 10,216 participants.

Worldwide trials of the shot have shown wide variations in efficacy rates, and the company has faced criticism for a lack of transparency regarding its trial findings.